Special Meeting Adjourned; Supermajority Voting Proposal Requires 75% Approval
Tempest Therapeutics reconvened its special meeting of stockholders on November 12, 2026, but adjourned the meeting because sufficient votes were not obtained to approve a proposal to replace supermajority voting requirements and permit stockholder action by written consent. A total of 11,052,422 shares (74.64% of outstanding shares) were present virtually or represented by proxy, but the proposal requires the affirmative vote of at least 75% of entitled votes. The company has engaged Sodali & Co. as a proxy sol...
Key takeaways
Meeting adjourned: The special meeting was adjourned because the proposal did not receive the required 75% affirmative vote threshold.
Quorum achieved: 11,052,422 shares (74.64% of 14,806,997 shares outstanding as of the May 28, 2026 record date) were present virtually or represented by proxy.
Proposal details: The proposal seeks to replace supermajority voting requirements and permit stockholder action by written consent.
Reconvened meeting: The special meeting will reconvene on December 11, 2026 at 12:00 p.m. Eastern Time via live webcast at www.virtualshareholdermeeting.com/TPST2026SM2.
Proxy solicitation: The company has engaged Sodali & Co. to assist with obtaining adequate votes to achieve the required quorum and approval.
Record date unchanged: The record date for determining stockholder eligibility to vote remains the close of business on May 28, 2026.
Primary source
TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.
Open SEC filingFollow TPST in real time
Get material earnings, filing, IR, and earnings-call alerts by email.